Inventor · disambiguated record
Martin C. Wright
Also filed as: WRIGHT MARTIN C
22 granted patents·5 pending applications·657 citations·filing 1994–2022
97Inventor score
Top patents by PatentIndex Score
27 records- 0198US7858739B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 28, 2010·84 cites·79 claims
- 0297US8324362B2Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptorsCHEN YAN·Filed 2010·Granted Dec 4, 2012·58 cites·10 claims
- 0397US7847062B2Pharmacokinetic modulation and compositions for modified FN3 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 7, 2010·77 cites·15 claims
- 0496US9862758B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 9, 2018·20 cites·22 claims
- 0596US9771411B2Method of treating cancer by administering EGFR and EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 26, 2017·22 cites·20 claims
- 0696US9017655B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Apr 28, 2015·36 cites·10 claims
- 0796US8609613B2Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptidesCHEN YAN·Filed 2012·Granted Dec 17, 2013·36 cites·20 claims
- 0896US8470332B2Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IRCAMPHAUSEN RAY·Filed 2007·Granted Jun 25, 2013·41 cites·13 claims
- 0996US8343501B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Jan 1, 2013·45 cites·19 claims
- 1095US10406251B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 10, 2019·15 cites·35 claims
- 1195US9328157B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted May 3, 2016·26 cites·7 claims
- 1293US6623926B1Methods for producing 5′-nucleic acid-protein conjugatesPHYLOS INC·Filed 2000·Granted Sep 23, 2003·46 cites·26 claims
- 1391US11173219B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 16, 2021·4 cites·21 claims
- 1491US10183987B2Polynucleotides encoding bispecific EGFR/IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 22, 2019·7 cites·13 claims
- 1591US6846655B1Methods for generating highly diverse librariesPHYLOS INC·Filed 1999·Granted Jan 25, 2005·119 cites·55 claims
- 1690US10954286B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 1790US10221232B2Methods of treating cancer by administering IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 5, 2019·7 cites·10 claims
- 1889US11344639B2PET imaging with PD-L1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 31, 2022·4 cites·13 claims
- 1983US10995131B2Libraries of modified fibronectin type III tenth domain-containing polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 4, 2021·1 cites·14 claims
- 2082US11149077B2Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IRBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 19, 2021·1 cites·10 claims
- 2174US12194110B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 14, 2025·0 cites·15 claims
- 2267US2013310317A1Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-irBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 2366US2022347324A1Pet imaging with pd-l1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2461US2015252097A1Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-irBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 2547US2008220049A1Compositions and methods for intraocular delivery of fibronectin scaffold domain proteinsADNEXUS A BRISTOL MYERS SQUIBB·Filed 2007·Application pending·0 cites
- 2641US2003032157A1Polypeptides interactive with Bcl-XLFiled 2002·Application pending·0 cites
- 2739US5650294AIsolated promoter and terminator of elongation factor 1-αBASF AG·Filed 1994·Granted Jul 22, 1997·6 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when Martin C. Wright files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →